No. It is a screening aid, not a diagnostic device. It produces a risk estimate to support clinical judgment. Patients with an elevated score are referred to a qualified provider for full clinical evaluation, such as a clinician-administered AIMS assessment. The clinician remains the decision-maker at every step.

Yes. TDScreen’s scoring aligns with the AIMS framework and has been evaluated in peer-reviewed clinical research.

By standardizing movement analysis, TDScreen reduces the variability that naturally occurs between human raters, giving your team a consistent, objective reference point across patients and across visits.

We have a very high level of predictability and sensitivity. We’re happy to share model cards or AUC data in a follow-up.

Equitable performance is a priority. TDScreen applies the same standardized analysis to every patient, removing individual-rater subjectivity.

You will receive a clinically structured summary of their results, making it easy to determine next steps. TDScreen is designed to support, not replace, your clinical judgment and offers clear guidance for follow-up conversations.

Yes, patients find the experience quick, simple, and non-intimidating. Most complete the screen in under five minutes.

Patients complete a screening only after being informed about what is captured and how it is used, and consent is recorded within the workflow. Because screening is patient-initiated on the patient’s own device, patients engage on their own terms.

Results are delivered to the provider and patient as an objective risk score. Follow-up responsibility stays with the clinical team, exactly as it does with any screening result.

TDScreen is designed to protect clinician time, not consume it. Because the roughly five-minute screen can be completed before, during, or between visits, including via telehealth, it frees the encounter for conversation and care rather than for administering a rating scale.

Yes, patients find the experience quick, simple, and non-intimidating. Most complete the screen in under five minutes.

All provider-led TDScreen sessions are fully HIPAA-compliant and SOC 2 Type II certified. Patient data and PHI are protected in accordance with these standards.

For transparency, TDScreen also runs consumer-facing advertisements to raise awareness of tardive dyskinesia. Sessions originating from these ads use standard analytics tools such as Google and Meta, which may record site activity but never have access to video recordings or individual assessment results.

Data is encrypted at rest (AES-256) and in transit (TLS 1.2 or higher), hosted on Amazon Web Services behind firewalls and standard security controls, with role-based access, continuous logging and auditing, and monitored privileged access. Videra Health is SOC 2 Type II certified, conducts third-party penetration testing and ongoing vulnerability scanning, and carries cybersecurity liability insurance.

No. TDScreen does not identify patients by their faces or infer identity from appearance. It analyzes involuntary movement to support screening based on the Abnormal Involuntary Movement Scale (AIMS), the same framework clinicians already use to assess TD. The ethical concerns most often raised about facial recognition, such as identity matching and appearance-based inference, do not apply to how TDScreen works.

Access is role-based and restricted, and client data is logically separated from that of other organizations. Customer data is never used for testing or development. Only limited de-identified data may be used for research and model improvement.

Videra Health maintains formal Data Protection and Data Management policies, with architecture and data-flow documentation available on request.

A BAA is not required to use TDScreen, but it is necessary to access the full suite of features, including the Provider Portal, which offers real-time visibility into your patients’ results.

If you’re unable to sign a BAA, no problem: you can still use TDScreen! We’ll provide you with a unique, secure link to share with patients. They can use this link to access and complete the TDScreen independently, receive their results, and then share those results with you.

Yes. Routine, structured screening for abnormal involuntary movements in patients on antipsychotics is long-established clinical practice, and structured instruments such as the AIMS are the recognized standard of care. TDScreen operationalizes that established standard more efficiently; it is not a new or unproven category of assessment.

No. It is a screening aid, not a diagnostic device. It produces a risk estimate to support clinical judgment. Patients with an elevated score are referred to a qualified provider for full clinical evaluation, such as a clinician-administered AIMS assessment. The clinician remains the decision-maker at every step.

TDScreen is designed and offered as a screening aid to support clinical decision-making, not as a standalone diagnostic device.

TDScreen supports, and does not replace, clinical judgment; the treating clinician interprets results and directs care.

Yes. TDScreen is completely free for providers and patients to use. There are no hidden fees.

Any licensed prescribing behavioral health provider treating patients on antipsychotic medications, including psychiatrists, psychiatric NPs, etc. Commonly used in settings such as private clinics, community-based services like CCBHCs, hospitals, and more. Available for individual providers, group practices, and multi-site organizations. Full implementation support included.

Very little. TDScreen is vendor-hosted and cloud-based, with no on-site hardware, no internal-network integration, and no special equipment; patients use a standard smartphone, tablet, or computer. It fits existing workflows and supports telehealth and remote-care models.

Most providers are live within 48 hours. For multi-provider or multi-site organizations, we’ll help onboard your team and align screening workflows.

A BAA is not required to use TDScreen, but it is necessary to access the full suite of features, including the Provider Portal, which offers real-time visibility into your patients’ results.

If you’re unable to sign a BAA, no problem: you can still use TDScreen! We’ll provide you with a unique, secure link to share with patients. They can use this link to access and complete the TDScreen independently, receive their results, and then share those results with you.

Yes. There’s no contract, no cost, and no obligation. You’re free to discontinue at any time.